# Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

> **NCT03786081** · PHASE1,PHASE2 · TERMINATED · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 214 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Tisotumab Vedotin
- **DRUG:** Bevacizumab
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03786081
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-27
- **Primary completion:** 2026-03-19
- **Final completion:** 2026-03-19
- **Target enrollment:** 214 (ACTUAL)
- **Why stopped:** Sponsor has decided to stop the trial based on strategic decisions
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03786081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03786081, "Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT03786081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*